SCHEMBL1958587

SCHEMBL1958587

C=CCN(CC=C)C(=O)CCC(N)=O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.65
SMN1; SMN2 Q16637 1/20 0.41
POLB P06746 1/20 0.38
DPP4 P27487 1/20 0.33
MAPT P10636 1/20 0.32
GRIN2D O15399 1/20 0.32
GRIN3B O60391 1/20 0.32
GRIN1 Q05586 1/20 0.32
GRIN2A Q12879 1/20 0.32
GRIN2B Q13224 1/20 0.32
GRIN2C Q14957 1/20 0.32
GRIN3A Q8TCU5 1/20 0.32
RAB9A P51151 1/20 0.32
LMNA P02545 2/20 0.31
HPGD P15428 1/20 0.31
ALOX12 P18054 1/20 0.31
CCR6 P51684 1/20 0.31
TSHR P16473 1/20 0.31
FGFR4 P22455 1/20 0.31
KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL316404 0.89 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2POLBDPP4MAPT
SCHEMBL16350574 0.89 ALDH1A1 (0.81) ALDH1A1SMN1; SMN2POLBDPP4MAPT
SCHEMBL3203831 0.80 ALDH1A1 (0.68) ALDH1A1SMN1; SMN2POLBDPP4MAPT
SCHEMBL571723 0.80 ALDH1A1 (0.68) ALDH1A1SMN1; SMN2POLBMAPTLMNA
SCHEMBL4070869 0.80 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2POLBDPP4MAPT
SCHEMBL8068413 0.79 ALDH1A1 (0.91) ALDH1A1SMN1; SMN2POLBDPP4MAPT
SCHEMBL10587120 0.77 ALDH1A1 (0.71) ALDH1A1SMN1; SMN2POLBDPP4MAPT
SCHEMBL7629952 0.77 ALDH1A1 (0.86) ALDH1A1SMN1; SMN2POLBMAPTRAB9A
SCHEMBL13630658 0.77 ALDH1A1 (0.86) ALDH1A1SMN1; SMN2POLBMAPTRAB9A
SCHEMBL15049827 0.77 ALDH1A1 (0.86) ALDH1A1SMN1; SMN2POLBMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456278-B2 Lactams substituted by cyclic succinates as inhibitors of Aβ protein production BRISTOL-MYERS SQUIBB PHARMA CORPORATION (US) 2008-11-25 US claimed
US-20080103128-A1 LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2008-05-01 US claimed
CN-117979943-A Emulsion antiperspirant compositions 联合利华知识产权控股有限公司 2024-05-03 CN disclosed
CN-117615745-A Process for the preparation of antiperspirant salts 联合利华知识产权控股有限公司 2024-02-27 CN disclosed
EP-4174115-A1 RADIATION CROSS-LINKING BOOSTERS FOR ALIPHATIC POLYAMIDES Thüringisches Institut für Textil- und Kunststoff-Forschung e.V. (DE) 2023-05-03 EP disclosed
EP-2750657-A1 BISUREA GELLING AGENTS AND COMPOSITIONS Milliken & Company (US) 2014-07-09 EP disclosed
WO-2013033300-A1 BISUREA GELLING AGENTS AND COMPOSITIONS MILLIKEN & COMPANY (US) 2013-03-07 WO disclosed
WO-2012072409-A2 PROCESS FOR TREATING BODY ODOUR COMBINING A TOPICAL DEODORANT PRODUCT WITH AN ORAL PERFUME; DEODORIZING KIT L'OREAL (FR) 2012-06-07 WO disclosed
WO-2011073440-A2 DEODORANT COMPOSITION BASED ON ANTIMICROBIAL PEPTIDES AND METHOD FOR TREATING BODY ODOUR L'OREAL (FR) 2011-06-23 WO disclosed
EP-1465585-B1 COSMETIC COMPOSITIONS COMPRISING A CYCLODIPEPTIDE COMPOUND UNILEVER PLC (GB) 2009-04-29 EP disclosed
US-20090062256-A1 LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2009-03-05 US disclosed
WO-2001092235-A1 LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-12-06 WO disclosed
US-6251377-B1 WATER IMMISCIBLE LIQUIDS, SILICONE OILS AND ORGANIC COMPOUNDS UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. 2001-06-26 US disclosed
US-6231841-B1 AN ANTIPERSPIRANT COMPRISING AN ANTIPERSPIRANT ACTIVE, A LIQUID CARRIER AND A STRUCTURANT INCLUDING A STEROL AND AN STEROL ESTER TO THICKEN OR SOLIDIFY THE ANTIPERSPIRANT UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. 2001-05-15 US disclosed
EP-1074246-A1 Cosmetic composition containing a structurant UNILEVER PLC (GB) 2001-02-07 EP disclosed
WO-2001007007-A1 COSMETIC COMPOSITIONS COMPRISING A CONTINUOUS PHASE UNILEVER PLC (GB) 2001-02-01 WO disclosed
EP-1064925-A2 Cosmetic compositions UNILEVER PLC (GB) 2001-01-03 EP disclosed
WO-2000074640-A1 ANTIPERSPIRANT COMPOSITIONS UNILEVER PLC (GB) 2000-12-14 WO disclosed
WO-2000061081-A2 STRUCTURED COSMETIC COMPOSITIONS UNILEVER PLC (GB) 2000-10-19 WO disclosed
EP-0087234-A1 Ashless dispersant compounds, their preparation, and their use in providing dispersancy in lubricating oils or liquid fuels EDWIN COOPER INC. (US) 1983-08-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062256-A1 LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION BACE1, APP, APH1A ALDH1A1 3203/4885SMN1; SMN2 520/4885POLB 840/4885
US-20080103128-A1 LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION APH1A, APH1B, APP ALDH1A1 2423/4885SMN1; SMN2 609/4885POLB 1673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.